Health and Fitness Health and Fitness
Tue, June 5, 2012
Mon, June 4, 2012
Sat, June 2, 2012
Fri, June 1, 2012
Thu, May 31, 2012
Wed, May 30, 2012
Tue, May 29, 2012
Mon, May 28, 2012
Sun, May 27, 2012
Sat, May 26, 2012
Fri, May 25, 2012
[ Fri, May 25th 2012 ] - Market Wire
GenVec Reports Inducement Award
Thu, May 24, 2012
Wed, May 23, 2012
[ Wed, May 23rd 2012 ] - Market Wire
Moody's Upgrades Mylan
Tue, May 22, 2012

Faruqi amp;; Faruqi, LLP Announces Investigation of ViroPharma Incorporated


//health-fitness.news-articles.net/content/2012/ .. es-investigation-of-viropharma-incorporated.html
Published in Health and Fitness on Tuesday, May 29th 2012 at 16:45 GMT by Market Wire   Print publication without navigation


Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated -- NEW YORK, May 29, 2012 /PRNewswire/ --

Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated

[ ]

NEW YORK, May 29, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at ViroPharma Incorporated ("ViroPharma" or the "Company") (NASDAQ: VPHM).

(Logo: [ http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ] )

The investigation focuses on the Company's product Vancocin, which uses the Vancomycin antibiotic.  On December 14, 2011, the Company issued a press release stating that it believed that Vancocin would have three years of marketing exclusivity due to changes in its label, and that generic Vancomycin capsules would not be approved during that period.  Following this news, ViroPharma's stock price rose 17.9% to close at $27.80 per share on December 14, 2011.

However, on April 10, 2012, ViroPharma announced that the FDA had informed the Company that Vancocin's new label would not qualify the product for three additional years of exclusivity, and that the FDA had indicated it is approving three applications for generic Vancomycin capsules.  Following this news, the price of ViroPharma common stock dropped 22% to close at $22.44 per share on April 10, 2012. 

Request more information now by clicking here:  [ www.faruqilaw.com/VPHM ]

Take Action
If you purchased ViroPharma securities between December 14, 2011 and April 9, 2012 and would like to discuss your legal rights, visit [ www.faruqilaw.com/VPHM ]. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [ rgonnello@faruqilaw.com ] or [ fmcconville@faruqilaw.com ].  Faruqi & Faruqi, LLP also encourages anyone with information regarding ViroPharma's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.


Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ([ www.faruqilaw.com ]).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
[ rgonnello@faruqilaw.com ]
Francis McConville, Esq.
[ fmcconville@faruqilaw.com ]
Telephone: (877) 247-4292 or (212) 983-9330

 

SOURCE Faruqi & Faruqi, LLP

[ Back to top ]

RELATED LINKS
[ http://www.faruqilaw.com ]


Publication Contributing Sources